Equities

ALVAL

FR0013254851

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 16:27:45 08/05/2024 BST			5-day change	1st Jan Change
4.665 ^EUR	+1.19%		+13.50%	-6.70%

04-26	Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-03	Valbiotis: launch of Valbiotis PRO Cholesterol in May	CF

Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023

April 26, 2024 at 10:01 am

Valbiotis SA reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 6.81 million compared to EUR 2.81 million a year ago. Net loss was EUR 7.37 million compared to EUR 12.31 million a year ago.

Latest news about VALBIOTIS

Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023	04-26	CI
Valbiotis: launch of Valbiotis PRO Cholesterol in May	04-03	CF
Valbiotis: capital increase successfully completed	12-22	CF
Valbiotis: 15 ME capital increase	12-12	CF
Valbiotis' Plant Extract Receives New Dietary Ingredient Status from US FDA	12-12	MT
Valbiotis SA Reports Earnings Results for the Half Year Ended June 30, 2023	28/09/23	CI
Valbiotis: share price rises on success of clinical study	12/09/23	CF
Valbiotis SA Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM 63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance	11/09/23	CI
VALBIOTIS : Invest Securities confirms its recommendation	17/07/23	CF
Global markets live: BP, Walt Disney, Amazon, PepsiCo, Delta Airlines....	13/07/23
Valbiotis: share price up, broker in support	25/05/23	CF
VALBIOTIS : Oddo BHF raises its target price	25/05/23	CF
Valbiotis: share price soars, broker adjusts target	23/05/23	CF
VALBIOTIS : promising study, Invest Sec. raises its target	23/05/23	CF
Valbiotis: 'major' breakthrough in type 2 diabetes	22/05/23	CF
Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM-63	22/05/23	CI
Global markets live: Deliveroo, Adobe, Berkshire Hathaway, First republic Bank, Robinhood Markets...	16/03/23
Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2022	14/03/23	CI
Valbiotis SA Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science	13/03/23	CI
Global markets live: GM, Pfizer, Exxon, UBS, Boeing...	31/01/23
Valbiotis: encouraging results in hypertension	30/01/23	CF
Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM--854 Clinical Study, Against High Blood Pressure	30/01/23	CI
Valbiotis SA Announces the Signature of a Research Partnership in Intestinal Microbiota With the MEDIS Unit From the Clermont Auvergne University	14/12/22	CI
Valbiotis SA announced that it has received €9.7 million in funding	08/11/22	CI
Valbiotis SA Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia	03/10/22	CI

Chart VALBIOTIS

Duration

Period

More charts

Company Profile

VALBIOTIS is a French Research & Development company committed to scientific innovation for the prevention and control of metabolic diseases. VALBIOTIS specializes in the development of innovative nutritional solutions for cardio-metabolic disease prevention and nutritional support for patients. The products are intended for food and pharmaceutical industries. VALBIOTIS is essentially intervening in the prevention of type 2 diabetes, NASH (non-alcoholic steatohepatitis), obesity and cardiovascular diseases. VALBIOTIS has established numerous partnerships with academic centers of excellence in France and overseas, including the University of La Rochelle, the CNRS, and the Clermont Auvergne University in Clermont-Ferrand where the company has opened a secondary school. With these agreements, since its inception VALBIOTIS has benefited from a strong leverage thanks notably to experts and technical partners involved in its projects.

Sector

Biotechnology & Medical Research

Calendar

24/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for VALBIOTIS

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.61 EUR

Average target price

10.07 EUR

Spread / Average Target

+118.37%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VALBIOTIS	-6.70%	78.38M
VERTEX PHARMACEUTICALS INCORPORATED	+3.33%	106B
ARGENX SE	+7.02%	23.47B
BIONTECH SE	-14.61%	21.9B
GENMAB A/S	-7.05%	18.77B
WUXI APPTEC CO., LTD.	-38.55%	17.85B
BEIGENE, LTD.	-9.10%	16.78B
NEUROCRINE BIOSCIENCES, INC.	+5.57%	14.41B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.86B
VIKING THERAPEUTICS, INC.	+328.40%	8.78B

Bio Therapeutic Drugs